证券代码：688596 证券简称：正帆科技 公告编号：2023-039 上海正帆科技股份有限公司 关于召开2022年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 上海正帆科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日在 上海证券交易所网站（www.sse.com.cn）披露了《上海正帆科技股份有限公司 2022 年年度报告》。为便于广大投资者更加全面深入地了解公司 2022 年年度经营成 果、财务状况，公司定于 2023 年 5 月 24 日（星期三）15:00-16:00 在"价值在 会议召开时间：2023 年 5 月 24 日（星期三）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 5 月 24 日 前 访 问 网 址 https://eseb.cn/14J3xUY0EIU 或扫描下方小程序码进行会前提问，公司将 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 410,811,629.30, representing a year-on-year increase of 13.42%[5] - The net profit attributable to shareholders was CNY 11,148,973.64, showing a slight decrease of 0.97% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses increased by 119.11% to CNY 7,350,436.81, driven by growth in core business and reduced bad debt provisions[10] - The company achieved new signed orders of RMB 1,478.61 million in Q1 2023, representing a year-on-year growth of 25.9%[21] - Net profit for Q1 2023 reached CNY 14,956,202.55, compared to CNY 11,900,029.50 in Q1 2022, representing a growth of 25.8%[34] - Total comprehensive income for Q1 2023 reached CNY 14,822,341.99, compared to CNY 11,776,953.94 in Q1 2022, reflecting an increase of approximately 26.0%[35] Research and Development - Research and development (R&D) expenses totaled CNY 34,245,247.87, up 111.51% year-on-year, accounting for 8.34% of operating revenue, an increase of 3.87 percentage points[5] - Research and development expenses in Q1 2023 were CNY 34,245,247.87, significantly higher than CNY 16,190,746.33 in Q1 2022, indicating a year-over-year increase of 111.5%[31] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 6,327,428,273.72, reflecting a 6.27% increase from the end of the previous year[5] - The total assets as of Q1 2023 were CNY 6,327,428,273.72, compared to CNY 5,954,001,018.81 in the previous year, indicating an increase of 6.3%[30] - The total liabilities as of Q1 2023 amounted to CNY 3,859,629,159.10, compared to CNY 3,540,949,003.60 in the previous year, marking an increase of 9.0%[30] - The company reported a total current liabilities of RMB 3,575.73 million as of March 31, 2023, compared to RMB 3,200.00 million at the end of 2022[26] - The company’s total equity increased to RMB 2,000.00 million as of March 31, 2023, up from RMB 1,800.00 million at the end of 2022[26] - The total equity attributable to shareholders of the parent company was CNY 2,456,750,761.92, up from CNY 2,407,810,891.42, reflecting a growth of 2.0%[30] Cash Flow - The net cash flow from operating activities was negative at CNY -129,857,764.49, primarily due to increased inventory payments compared to the same period last year[10] - Cash inflow from operating activities totaled CNY 533,346,334.07, up from CNY 472,286,569.12 in Q1 2022, indicating a growth of about 12.9%[36] - Cash outflow from operating activities increased to CNY 663,204,098.56, compared to CNY 489,682,427.06 in Q1 2022, representing a rise of approximately 35.4%[36] - Cash flow from investing activities showed a net outflow of CNY -81,674,083.27, an improvement from CNY -124,418,496.75 in the previous year[36] - Cash flow from financing activities resulted in a net outflow of CNY -84,268,269.57, compared to a net inflow of CNY 147,373,105.05 in Q1 2022[36] - The company reported a total cash and cash equivalents balance of CNY 920,152,648.45 at the end of Q1 2023, down from CNY 617,282,822.22 at the end of Q1 2022[38] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,298[14] - As of March 31, 2023, the company completed a share buyback totaling 4,351,088 shares, with 800,000 shares allocated to the employee stock ownership plan[22] - The company plans to utilize the remaining 3,551,088 shares from the buyback for employee stock ownership or equity incentive plans[22] Other Financial Metrics - The basic and diluted earnings per share were both CNY 0.04, unchanged from the previous year[5] - The weighted average return on equity was 0.46%, a decrease of 0.14 percentage points compared to the previous year[5] - The company received government subsidies amounting to CNY 3,552,292.61 during the reporting period[9] - The company experienced a negative impact of CNY -567,587.46 from foreign exchange fluctuations on cash and cash equivalents[38] - The deferred income tax liabilities increased to CNY 22,210,175.84 from CNY 12,640,630.31, showing a rise of 75.5%[30] - The company's cash and cash equivalents decreased to RMB 927.11 million from RMB 1,223.73 million year-on-year[23] - Accounts receivable increased to RMB 844.83 million from RMB 821.38 million year-on-year[23] - Inventory rose significantly to RMB 2,479.71 million compared to RMB 1,983.41 million in the previous year[23] - The company’s retained earnings reached CNY 671,566,311.93, up from CNY 660,417,338.29, reflecting a growth of 1.8%[30] - The company reported a financial expense of CNY 5,559,548.67 in Q1 2023, compared to a financial income of CNY -94,757.28 in Q1 2022[31]

Financial Performance - In 2022, Shanghai Zhengfan Technology achieved a sales revenue of 2.7 billion RMB and a net profit attributable to shareholders of 259 million RMB, with a six-year compound annual growth rate (CAGR) of 30% for sales and 54% for net profit[4]. - Shanghai Gentech reported a revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-over-year growth of 15%[25]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year growth of 20%[174]. - The company’s operating revenue for 2022 reached ¥2,704,742,573.87, representing a 47.26% increase compared to ¥1,836,764,431.27 in 2021[26]. - Net profit attributable to shareholders increased by 53.61% to ¥258,675,666.49 from ¥168,402,808.59 in the previous year[28]. - The company reported a net profit increase of 46.83%, with retained earnings reaching 660,417,338.29, which is 11.09% of total equity, compared to 449,778,020.51 (12.82%) last year[138]. Investment and Growth Strategy - The company plans to leverage capital expenditure (Capex) business to expand its operational expenditure (Opex) business, anticipating a strong growth momentum driven by increasing Opex as new production capacities come online[5]. - The company plans to increase its capital expenditure (Capex) by 20% in 2023 to support new product development and market expansion initiatives[25]. - The company is focused on expanding its biopharmaceutical and semiconductor equipment sectors as part of its future development strategy[154]. - The company aims to enhance its competitive position by offering a comprehensive range of products and services, responding to the diverse needs of customers in the semiconductor industry[84]. - The company will continue to utilize capital market mechanisms for financing to support business development plans, including investments in electronic specialty gases and advanced materials[162]. Research and Development - The company will continue to invest in the development of electronic specialty gases, advanced materials, and digital operation platforms, ensuring the launch of new products and enhancement of supply capabilities[5]. - The company increased its R&D investment by 91.65% year-on-year, with a 60% increase in R&D personnel[44]. - The company has developed six core technologies related to electronic gases and chemicals, including micro-pollution control technology and fluid system design, enhancing its competitive edge in the market[86][87]. - R&D investment increased by 91.65% year-on-year, reaching approximately ¥149.91 million, driven by higher material consumption and an increase in R&D personnel[92][93]. - The company is focusing on self-research and development of electronic specialty gases and advanced materials, leveraging its core technologies[68]. Market Expansion - Gentech is expanding its market presence in Southeast Asia, with plans to establish a new manufacturing facility in Vietnam by Q4 2023[25]. - The company plans to expand its market presence, with plans to enter two new regional markets in 2023, which is expected to increase market share by 10%[175]. - The company is positioned to benefit from the rapid growth in fixed asset investment in downstream markets, which is expected to continue generating new orders[5]. - The semiconductor industry in China is expected to see significant growth due to increased fixed asset investment and a focus on domestic production capabilities[80]. Risk Management - The company has outlined various risks in its operations and has measures in place to address these risks, urging investors to be mindful of investment risks[8]. - The company faces risks related to supply chain disruptions, particularly for core raw materials and components, which could adversely affect production and operational sustainability[106]. - Ongoing international trade tensions, particularly between China and the U.S., pose risks to the company's market sales and product supply chains[109]. Corporate Governance and Management - The company has committed to maintaining a long-term focus on revitalizing the national technology industry and enhancing employee value through incentive mechanisms[6]. - The company emphasizes improving information disclosure and investor relations management, enhancing understanding of its business among investors[47]. - The company has implemented an employee incentive mechanism, including stock options, to foster the growth of high-potential talent and align their interests with the company's long-term goals[103]. - The company has established a three-year shareholder return plan for 2022-2024, focusing on sustainable returns to investors[183]. Product Development - Gentech aims to launch three new semiconductor products in 2023, targeting a market share increase of 5% in the high-performance chip segment[25]. - The company is set to launch three new products in the next quarter, anticipated to generate significant interest and sales[173]. - New product development includes the launch of three innovative gas products aimed at the industrial sector, projected to contribute an additional 200 million RMB in revenue[174]. Financial Management - The company does not plan to distribute cash dividends or conduct capital reserve transfers for 2022, focusing instead on supporting necessary business development needs[10]. - The company’s gross profit margin for the integrated circuit segment was 25.72%, a decrease of 4.21 percentage points year-on-year[116]. - The company’s revenue from the East China region was 1,386.77 million RMB, representing a year-on-year increase of 29.15%[117]. - The financing activities generated a net cash flow of 1,097.61 million RMB, a significant increase from 58.15 million RMB in the previous year[112]. Sustainability and Innovation - The management team emphasized a commitment to sustainability, aiming for a 25% reduction in carbon emissions by 2025 through innovative practices and technologies[175]. - The company has developed recycling services for gases and wet chemicals to reduce emissions in semiconductor processes, including helium and VOC recovery systems[66]. - The company is increasing its R&D efforts in advanced electronic materials, transitioning from trading to self-research and production, thereby broadening its product range[63].

证券代码：688596 证券简称：正帆科技 上海正帆科技股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | --- | --- | --- | --- | |----------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：688596 证券简称：正帆科技 上海正帆科技股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | --- | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：688596 证券简称：正帆科技 上海正帆科技股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥860,815,447.11, representing a year-on-year increase of 92.44%[6] - The net profit attributable to shareholders for Q3 2022 was ¥84,363,906.39, an increase of 58.33% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥82,325,807.44, reflecting a 93.01% increase year-on-year[6] - The net profit attributable to shareholders increased by 27.67% year-on-year, reaching CNY 167.87 million, with a growth of 46.25% after excluding share-based payment factors[28] - The net profit attributable to shareholders after deducting non-recurring gains and losses grew by 37.87% year-on-year, amounting to CNY 157.87 million, with a growth of 58.54% after excluding share-based payment factors[28] - Net profit for the third quarter of 2022 reached CNY 138,578,665.56, an increase from CNY 107,456,060.59 in the same period last year, representing a growth of approximately 29%[38] - The company's operating profit for the third quarter was CNY 148,794,179.58, up from CNY 119,945,646.99, indicating a year-over-year increase of about 24%[38] - The total comprehensive income for the third quarter was CNY 139,528,824.81, compared to CNY 107,364,419.67 in the prior year, showing an increase of around 30%[41] - Basic earnings per share rose to CNY 0.54, up from CNY 0.42, representing a growth of approximately 29%[43] Research and Development - The total R&D investment for Q3 2022 was ¥47,124,463.47, which is 120.70% higher than the same period last year[9] - R&D investment accounted for 5.47% of operating revenue, an increase of 0.70 percentage points compared to the previous year[9] - Research and development expenses surged to CNY 91,587,327.13, compared to CNY 48,249,907.32 in the previous year, reflecting an increase of approximately 90%[38] - The company plans to continue investing in R&D to drive future growth and innovation[38] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥4,975,832,102.65, marking a 41.86% increase from the end of the previous year[9] - Current assets totaled RMB 3,945,794,710.46 as of September 30, 2022, up from RMB 2,698,048,153.03 at the end of 2021, reflecting a growth of approximately 46.3%[30] - Total liabilities reached RMB 3,017,834,130.91, compared to RMB 1,640,529,316.29 in the previous year, representing an increase of about 83.8%[35] - The company's cash and cash equivalents rose to RMB 788,342,682.50 from RMB 620,852,044.74, an increase of approximately 27%[30] - Non-current assets totaled RMB 1,030,037,392.19, up from RMB 809,610,240.47, reflecting a growth of about 27.2%[33] - The company's retained earnings increased to RMB 553,110,801.20 from RMB 449,778,020.51, showing a growth of approximately 22.9%[35] - The total assets of the company reached RMB 4,975,832,102.65, compared to RMB 3,507,658,393.50 in the previous year, indicating an increase of about 41.9%[35] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥132,547,971.41, indicating a cash outflow[6] - Cash inflow from operating activities totaled CNY 1,495,563,823.30, significantly higher than CNY 914,803,008.97 in the same period last year, indicating an increase of about 63%[43] - The net cash flow from operating activities was -$132.55 million, compared to -$58.77 million in the previous period, indicating a decline in operational performance[45] - Total cash inflow from investing activities was $98.58 million, down from $206.16 million, while cash outflow for investing activities was $309.44 million, compared to $354.87 million previously[45] - The net cash flow from financing activities increased significantly to $504.39 million, up from $19.61 million, reflecting improved capital raising efforts[45] - The company reported a net increase in cash and cash equivalents of $166.84 million, contrasting with a decrease of -$187.65 million in the prior period[45] - The ending balance of cash and cash equivalents was $779.46 million, compared to $603.69 million at the end of the previous period, showing a strong liquidity position[45] - Cash received from borrowings was $656.55 million, a substantial increase from $52.90 million, indicating aggressive financing strategies[45] - Cash outflow for dividend payments and interest was $41.38 million, compared to $25.93 million, reflecting a higher return to shareholders[45] - The company experienced a foreign exchange impact of $5.86 million on cash and cash equivalents, compared to $0.21 million previously, highlighting currency fluctuations[45] - Cash inflow from investment activities included $90.33 million from recovering investments, down from $198 million, indicating a decrease in investment recovery[45] - The net cash flow from investing activities was -$210.86 million, worsening from -$148.71 million, suggesting increased capital expenditures or investments[45] Shareholder Information - As of September 30, 2022, the total number of ordinary shareholders was 6,888, with the largest shareholder holding 20.67% of the shares[21] - The company repurchased a total of 4,351,088 shares, accounting for 1.69% of the total share capital, with a repurchase price not exceeding CNY 33.10 per share[28] - The stock option incentive plan allowed for the exercise of 5,996,100 shares, with 1,251,356 shares exercised by September 30, 2022, representing 20.87% of the total[28] - The company plans to use between CNY 80 million and CNY 120 million for share repurchase, aimed at employee stock ownership plans or equity incentives[28] - The top ten shareholders include significant holdings from both domestic individuals and foreign entities, with the largest individual shareholder holding 5.30%[21] - The company’s total share capital increased from 256,500,000 shares to 257,751,356 shares due to stock option exercises[28] - The company’s stock status includes frozen shares due to inquiry transfer business, specifically for one of the investment partnerships[25] - The company received approval from the China Securities Regulatory Commission for a simplified issuance of shares to specific targets on October 11, 2022[28]

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a 15% increase compared to the same period last year[16]. - The company's operating revenue for the first half of the year reached ¥943,124,795.58, representing a 19.70% increase compared to ¥787,914,893.43 in the same period last year[21]. - The net profit attributable to shareholders decreased by 2.48% to ¥52,827,430.20 from ¥54,171,019.01 year-on-year, while the net profit excluding non-recurring gains and losses fell by 9.54% to ¥44,868,162.90[21]. - The basic earnings per share remained stable at ¥0.21, while the diluted earnings per share was not reported; the basic earnings per share after excluding non-recurring gains and losses decreased by 5.26% to ¥0.18[24]. - The weighted average return on net assets decreased by 0.35 percentage points to 2.78% compared to the previous year[24]. - The net cash flow from operating activities showed a net outflow of ¥92,515,038.93, worsening from a net outflow of ¥42,854,626.37 in the same period last year[21]. - The company's total assets increased by 24.82% to ¥4,378,256,183.56 compared to ¥3,507,658,393.50 at the end of the previous year[21]. - The company's operating costs rose by 18.05% to 696,257,320.51 RMB, in line with the increase in operating revenue[84]. - The inventory level increased by 44.72% to 1,537,069,004.56 RMB, attributed to the expansion of business scale and increased stock of raw materials[88]. - The company reported a significant increase in accounts receivable, which rose by 28.73% to 641,363,974.37 RMB, reflecting higher sales revenue[88]. Research and Development - The company is investing 50 million RMB in R&D for new technologies aimed at enhancing product efficiency and reducing costs[16]. - Research and development expenses accounted for 4.71% of operating revenue, an increase of 1.30 percentage points from the previous year[24]. - The company achieved a total R&D investment of ¥44,462,863.66 in the first half of 2022, representing a 65.31% increase compared to ¥26,897,231.57 in the same period last year[52]. - The company applied for 10 invention patents and 38 utility model patents during the reporting period, bringing the total number of intellectual property rights to 141, including 25 invention patents and 108 utility model patents[48]. - The company has developed six core technologies, including micro-pollution control technology and fluid system design, enhancing its capabilities in high-purity special gas synthesis and purification[46]. - The number of R&D personnel has increased to 278, representing 23.36% of the total workforce, up from 16.74% in the previous year[62]. - The average salary of R&D personnel has risen to ¥11.19 million, compared to ¥8.89 million in the previous year[62]. Market Expansion and Strategy - The company has set a revenue guidance of 1.2 billion RMB for the full year 2022, which reflects a projected growth of 10% year-over-year[16]. - Market expansion plans include entering two new international markets by the end of 2022, targeting a 30% increase in overseas sales[16]. - The company aims to enhance its market share in high-tech industries, focusing on semiconductor, photovoltaic, and biopharmaceutical sectors[38]. - The company is actively expanding its service operations (OPEX) business, providing electronic gas chemicals and MRO services to downstream industries[31]. - The company is focusing on expanding its product offerings in the semiconductor industry, particularly in high-purity chemical filling systems[59]. - The company is developing a new generation of systems to enhance the efficiency and stability of liquid delivery processes in the semiconductor manufacturing sector[59]. Risk Management - The management has identified key risks including supply chain disruptions and regulatory changes, with strategies in place to mitigate these risks[16]. - The company is facing risks related to the reliance on imported raw materials due to the underdeveloped domestic supply chain for semiconductor components[79]. - The company has established long-term strategic partnerships with key suppliers to ensure supply chain stability and product quality[70]. Corporate Governance and Compliance - No significant changes in corporate governance or management structure were reported during the first half of 2022[16]. - The company has not reported any environmental complaints or pollution incidents during the reporting period, adhering to environmental protection laws and regulations[111]. - The company has implemented measures to ensure compliance with environmental standards, with no administrative penalties reported during the period[114]. - The company has established strict guidelines for related party transactions to ensure fairness and compliance with legal requirements[140]. Financial Commitments and Shareholder Relations - The company has committed to a shareholder dividend return plan to protect the interests of shareholders, especially minority shareholders[177]. - The company guarantees that there will be no fraudulent issuance of shares during the IPO process, with a commitment to repurchase shares if any fraudulent activities are confirmed[179]. - The company will publicly disclose reasons for any failure to fulfill commitments and will compensate investors for losses incurred due to non-compliance[183]. - The company has not proposed any profit distribution or capital reserve transfer plans for the reporting period[105]. - The company will ensure compliance with the relevant laws and regulations when reducing its holdings in Zhengfan Technology[150]. Investment and Fundraising - The company reported a total fundraising amount of RMB 1,006,569,454.49, with a net amount of RMB 910,722,926.13 after deducting issuance costs[195]. - As of the end of the reporting period, the cumulative investment amount from fundraising was RMB 518,933,026.37, representing a progress rate of 56.98%[195]. - The project for the expansion of ultra-pure arsine and phosphine production has a total fundraising commitment of RMB 181,530,000.00, with only RMB 24,813,620.70 invested so far, indicating a progress rate of 13.67%[198]. - The company has committed RMB 180,000,000.00 for working capital, which has been fully utilized[198].

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.32 CNY per 10 shares, totaling 33,858,000 CNY (including tax) based on a total share capital of 256,500,000 shares as of December 31, 2021, resulting in a cash dividend payout ratio of 20.11%[5] - The board of directors has approved the profit distribution plan, which is subject to shareholder approval at the annual general meeting[5] Financial Performance - The company's operating revenue for 2021 was ¥1,836,764,431.27, representing a 65.63% increase compared to ¥1,108,985,484.16 in 2020[25] - The net profit attributable to shareholders for 2021 was ¥168,402,808.59, a 35.53% increase from ¥124,258,067.95 in 2020[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥137,449,567.90, showing an 84.61% increase from ¥74,455,483.92 in 2020[25] - The company's net cash flow from operating activities improved by ¥36,327,800, reaching -¥19,636,751.32 in 2021, compared to -¥55,964,976.84 in 2020[25] - The total assets at the end of 2021 were ¥3,507,658,393.50, a 24.12% increase from ¥2,826,014,927.27 at the end of 2020[25] - The net assets attributable to shareholders at the end of 2021 were ¥1,864,400,246.86, reflecting a 9.36% increase from ¥1,704,790,258.84 at the end of 2020[25] - The basic earnings per share for 2021 was ¥0.66, up 13.79% from ¥0.58 in 2020[27] Research and Development - The R&D expenditure as a percentage of operating revenue was 4.26% in 2021, a decrease of 0.47 percentage points from 4.73% in 2020[27] - Research and development investment reached CNY 78.22 million, a year-on-year increase of 49.02%, accounting for 4.26% of operating revenue[38] - The company has obtained a total of 135 intellectual property rights, including 25 invention patents, 103 utility model patents, 5 design patents, and 2 software copyrights[38] - The company has developed six core technologies in electronic specialty gases and chemical products, enhancing its production and sales capabilities[119] - The company has filed 24 new patent applications this year, with 22 patents granted, bringing the cumulative total to 166 applications and 135 granted[123] Market and Industry Position - The company actively expanded its market presence in emerging industries such as new energy and new materials, in addition to its existing focus on high-end manufacturing sectors[38] - The company has established itself as a leading domestic player in electronic process equipment, participating in the development of 7 national standards and serving major clients like SMIC and Samsung[84] - The company is focused on enhancing its core competitiveness through continuous innovation and improvement of product quality[38] - The company is committed to autonomous research and development, continuously optimizing its core technologies to enhance product purity and production efficiency[119] Operational Risks and Governance - The company has detailed various operational risks and corresponding mitigation measures in the report, emphasizing the importance of investor awareness regarding investment risks[4] - The company has confirmed that all board members were present at the board meeting, ensuring governance transparency[4] - There are no non-operational fund occupations by controlling shareholders or related parties reported[4] - The company does not have any special arrangements for corporate governance that would affect its operations[5] - The company has not violated any regulatory decision-making procedures regarding external guarantees[4] Future Outlook and Strategic Developments - The company expects continued growth driven by the expansion of downstream industries and effective cost control measures[27] - The company has stated that future plans and strategic developments are forward-looking statements and do not constitute substantive commitments to investors[5] - The company aims to achieve a 90% application rate of cloud technology and artificial intelligence by 2025, which will drive high-quality and intelligent development in the pharmaceutical equipment sector[109] Challenges and Risks - The company faces risks related to technology upgrades and potential loss of core technical personnel, which could impact its competitive edge[149][150] - The ongoing COVID-19 pandemic poses uncertainties that could impact the company's operations and supply chain efficiency[158] - The company faces risks related to market competition as the semiconductor industry heats up, potentially affecting product scarcity and customer retention[154] Subsidiaries and Investments - The company established several new subsidiaries in 2021, including Tongling Zhengfan Electronic Materials Co., Ltd. and Hongge Semiconductor Equipment (Shanghai) Co., Ltd.[172] - The company established two new subsidiaries: Zhengfan Baotai (Suzhou) Technology Co., Ltd. in November 2021 and Zhengfan Technology (Lishui) Co., Ltd. in December 2021[175] - The company made six new equity investments totaling ¥89,490,000, indicating a strategic expansion in its investment portfolio[188]

2022 年第一季度报告 证券代码：688596 证券简称：正帆科技 上海正帆科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 YU DONG LEI(俞东雷)、主管会计工作负责人 ZHENG HONG LIANG(郑鸿亮)及会计机构 负责人（会计主管人员）刘小青保证季度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 | --- | --- | --- | --- | --- | --- | |------------------------------------------------|----------|-------|----------------|-------|-------------------------------------| | ...